Is Hyperliquid Spot Orderbook a Good Investment?
| TVL | $156M |
| FDV | $39.7B |
| TVL/FDV | 0.00x |
| Risk Grade | C+ |
| Value Grade | C+ |
Value Accrual: Does the Hyperliquid Spot Orderbook Token Capture Value?
Hyperliquid Spot Orderbook scores C+ on Hindenrank's value accrual framework (55/100), indicating average value capture — some strengths offset by weaknesses in fee distribution or sustainability. Fee capture scores 18/25 — solid, capturing a reasonable share of protocol revenue. Token distribution is rated 10/25 (somewhat concentrated, raising concerns about governance capture), and emission sustainability sits at 14/25. The competitive moat dimension scores 13/25.
Protocol Health: Is Hyperliquid Spot Orderbook Still Growing?
Hyperliquid Spot Orderbook's vitality risk score is 3/10 on Hindenrank's rubric (lower is healthier). This indicates strong protocol health — active development, growing TVL, and an engaged community. Hyperliquid Spot Orderbook shows signs of a thriving ecosystem that continues to attract users and developers.
Risk-Adjusted View: Is the Upside Worth the Risk?
Risk-Adjusted Position
NeutralHyperliquid Spot Orderbook sits in the Neutral zone — average on both risk (C+) and value (C+). There is no strong reason to overweight or avoid the token at current levels. Monitor for catalysts that could shift the balance in either direction.
Risk Context
Hyperliquid Spot Orderbook carries a risk grade of C+ (41/100), classified as elevated risk — multiple novel mechanisms and notable interaction risks. While no critical-severity interactions were identified, 2 high-severity interactions warrant attention. The primary risk factor is: HIP-1 token deployment via Dutch auction creates thin-liquidity listings that are easily manipulated — the JELLY-style attack vector applies to spot markets
Read our full safety analysis →Where Hyperliquid Spot Orderbook Sits Among DEX Peers
On risk, Hyperliquid Spot Orderbook ranks #84 of 111 DEX protocols (below-median — riskier than average). That's 7 points riskier than the sector average of 34/100.
The closest peer by risk profile is Bluefin Spot (grade C+, 41/100). See the side-by-side comparison to weigh their tradeoffs.
Should you buy Hyperliquid Spot Orderbook?
Hyperliquid Spot Orderbook scores C+ on Hindenrank's value accrual framework, placing it among the average DEX protocols. Fee capture scores 18/25 — solid, capturing a reasonable share of protocol revenue. Token distribution is somewhat concentrated, raising concerns about governance capture, and emission sustainability sits at 14/25. On the risk side, Hyperliquid Spot Orderbook carries a C+ grade (41/100), which is elevated risk — multiple novel mechanisms and notable interaction risks. The combined risk-value position places Hyperliquid Spot Orderbook in the Neutral quadrant.
Hyperliquid Spot Orderbook investment outlook for 2026
With $156M in total value locked and FDV of $39.7B, giving a TVL/FDV ratio of 0.00, Hyperliquid Spot Orderbook's fundamentals do not strongly support the current valuation from a usage perspective. The competitive moat dimension scores 13/25, suggesting meaningful but not impregnable competitive advantages.Investors should weigh these fundamentals alongside market conditions and their own risk tolerance.
This analysis is based on cryptoeconomic fundamentals, not price prediction. It is not financial advice. Full methodology
Weekly Commentary
ProWeek of April 8, 2026
Hyperliquid Spot Orderbook holds $169M TVL. The March 2025 JELLY token manipulation incident (already captured in track record score) remains the key historical risk event. No new incidents detected since last scan. The centralized sequencer architecture continues to operate without outages, though the reliance on Hyperliquid validators for delisting decisions (as in the JELLY event) demonstrates the governance trade-off inherent in the design.
Exploring options?
Compare DEX Alternatives →Related DEX Investment Analyses
Related DEX Safety Analyses
Get risk alerts before it's too late
Weekly grade changes, downgrade alerts, and new protocol risk findings. Free.